Thermo Fisher Supports Biopharma Advancements, Expands Drug Development Services

Thermo Fisher Scientific's clinical research business has entered into a contract with Quantum BioPharma to support a Phase 2 trial focused on progressive multiple sclerosis. This collaboration aims to implement Quantum BioPharma's Lucid-MS trial, which will investigate a potential new treatment for the condition.

Further demonstrating its commitment to advancing biopharmaceutical research, Thermo Fisher Scientific is also showcasing its latest solutions and enhanced capabilities designed to expedite the drug development process. These offerings are being presented at CPHI Milan 2026, a significant event for the pharmaceutical industry. The company's participation highlights its role in providing tools and services that help accelerate the journey from discovery to market for new therapies.

Industry coverage today also touches on broader themes within the biopharmaceutical sector, including initiatives like the Digital CMC Consortium. While not directly detailing Thermo Fisher's involvement in this specific consortium, reports suggest the company is actively contributing to the ecosystem that enables pharmaceutical innovation. Its diverse services and solutions position it as a key partner for companies navigating the complex landscape of drug development and clinical research.

Thermo Fisher Scientific's focus on supporting critical clinical trials, such as the one for multiple sclerosis, alongside its efforts to showcase broader drug development acceleration tools, underscores its strategic importance in the life sciences industry. The company's ongoing work aims to address unmet medical needs by facilitating the progress of potential new medicines.